101
|
Dindot S, Piccolo P, Grove N, Palmer D, Brunetti-Pierri N. Intrathecal injection of helper-dependent adenoviral vectors results in long-term transgene expression in neuroependymal cells and neurons. Hum Gene Ther 2011; 22:745-51. [PMID: 21175294 DOI: 10.1089/hum.2010.147] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Helper-dependent adenoviral (HDAd) vectors are devoid of all viral genes and result in long-term transgene expression in the absence of chronic toxicity. Because of their ability to infect post-mitotic cells, including cells of the central nervous system, HDAd vectors are particularly attractive for brain-directed gene therapy. In this study, we show that intrathecal injection of HDAd results in extensive transduction of ependymal cells and sustained expression of the transgene up to 1 year post-administration. We also demonstrate, for the first time, the ability of HDAd injected by this route of delivery to transduce neuronal cells. The transduced neuroepithelial cells can be potentially used to secrete therapeutic proteins into the cerebrospinal fluid and provide them via cross-correction to nontransduced cells. Targeting of neuronal cells and long-term transgene expression make this approach attractive for the treatment of several neurologic diseases.
Collapse
|
102
|
Stahle CM, Shi ZQ, Hu K, Barthelmy SD, Snodgrass SJ, Lehtonen SJ, Mach KJ, Barbier L, Gehrels N, Krizmanic JF, Palmer D, Parsons AM, Shu P. Fabrication of CdZnTe Strip Detectors for Large Area Arrays. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-487-257] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AbstractA CdZnTe strip detector large area array (∼ 60 cm2 with 36 detectors) with capabilities for high resolution imaging and spectroscopy has been built as a prototype for a space flight gamma ray burst instrument. The detector array also has applications in nuclear medical imaging. Two dimensional orthogonal strip detectors with 100 μm pitch have been fabricated and tested. Details for the array design, fabrication and evaluation of the detectors will be presented.
Collapse
|
103
|
Cui H, Palmer D, Zhou O, Stoner BR. Aligned Carbon Nanotubes Via Microwave Plasma Enhanced Chemical Vapor Deposition. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-593-39] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTAligned multi-wall carbon nanotubes have been grown on silicon substrates by microwave plasma enhanced chemical vapor deposition using methane/ammonia mixtures. The concentration ratio of methane/ammonia in addition to substrate temperature was varied. The morphology, structure and alignment of carbon nanotubes were studied by scanning electron microscopy and transmission electron microscopy. Both concentric hollow and bamboo-type multi-wall carbon nanotubes were observed. Growth rate, size distribution, alignment, morphology, and structure of carbon nanotubes changed with methane/ammonia ratio and growth temperature. Preliminary results on field emission properties are also presented.
Collapse
|
104
|
Young B, Schliesleder M, Rogers C, Clausen W, Felix C, Andrews S, Shaake B, Palo A, Ogundipe A, Miranda R, Merritt D, Kawasaki C, Fuller S, Cho I, Taylor J, Nafziger D, Pope P, Tarter A, Eldridge M, Hamm B, Carter Y, Garrigan V, George V, Macero K, Lance J, Sterner J, Eure K, Neunuebel MJ, Harvie J, Snyder A, Tafoya M, Quinn A, Rawlins C, Leach T, DiLascio M, Smith K, Rasmussen S, Dowell B, Hafner A, Clarke J, Travers D, McCormick L, Stubbs D, Johnson D, Sandel R, Brumley K, Russell B, Whitney B, Daniels S, Webb E, Palmer D, Bates R, Brindo D, T-Yocum M, Gonzalez K. Doing God's work, following in Mother Teresa's footsteps: 50 home care and hospice nurses serving patients in each of the 50 states and the District of Columbia. CARING : NATIONAL ASSOCIATION FOR HOME CARE MAGAZINE 2010; 29:38-69. [PMID: 21043327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
|
105
|
El Miedany Y, El Gaafary M, Youssef SS, Palmer D. Incorporating patient reported outcome measures in clinical practice: development and validation of a questionnaire for inflammatory arthritis. Clin Exp Rheumatol 2010; 28:734-744. [PMID: 20883639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2010] [Accepted: 05/18/2010] [Indexed: 05/29/2023]
Abstract
BACKGROUND Rheumatology is embarking on a fundamental redesign of rheumatic disease care. It has become mandatory not only to recognise disease activity core set data, but also the risks for other co-morbidities associated with inflammatory arthritis. Measurement of patient reported outcomes have become critical in both standard clinical practice and long term observational studies. OBJECTIVES To assess validity, reliability and responsiveness to change of a patient self-reported questionnaire which can assess construct outcome measures of patients with inflammatory arthritis. METHODS Four hundred and sixty-two patients with inflammatory arthritis were included in this work. The questionnaire was developed by integrating information obtained from patients suffering from inflammatory arthritis based on the Rasch model for ordered response options. The questionnaire includes assessment for functional disability, quality of life, VAS for joint pain, global status, fatigue, duration of morning stiffness, review of the systems, falls and cardiovascular risks, self-helplessness, as well as self reported joint pain. RESULTS The questionnaire was reliable as demonstrated by a high-standardised alpha (0.891-0.992). The questionnaire items correlated significantly (p<0.01) with clinical parameters of disease activity. RA patient reported tender joints correlated significantly with the physician's scores (0.842). Changes in functional disability, quality of life as well as self-helplessness scores showed significant (p<0.01) variation with disease activity status. The PROMs questionnaire also showed a high degree of comprehensibility.(9.4). CONCLUSIONS Integrating patient reported outcome measures into standard clinical practice is feasible and applicable. This version of a multidimensional questionnaire was found to be valid and reliable. It provides informative quantitative measures for the disease activity core set data, and in the mean time, facilitates assessing the patients' health related quality of life measure, cardiovascular and falls risks on an individual basis.
Collapse
|
106
|
Donahoe J, Palmer D, Burgos J. The unit of selection: what do reinforcers reinforce? J Exp Anal Behav 2010; 67:259-73. [PMID: 16812845 PMCID: PMC1284606 DOI: 10.1901/jeab.1997.67-259] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
107
|
Puntel M, Muhammad AKMG, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Bondale NS, Lerner J, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. J Virol 2010; 84:6007-17. [PMID: 20375153 PMCID: PMC2876634 DOI: 10.1128/jvi.00398-10] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2010] [Accepted: 03/29/2010] [Indexed: 01/03/2023] Open
Abstract
Glioblastoma multiforme (GBM) is a deadly primary brain tumor. Conditional cytotoxic/immune-stimulatory gene therapy (Ad-TK and Ad-Flt3L) elicits tumor regression and immunological memory in rodent GBM models. Since the majority of patients enrolled in clinical trials would exhibit adenovirus immunity, which could curtail transgene expression and therapeutic efficacy, we used high-capacity adenovirus vectors (HC-Ads) as a gene delivery platform. Herein, we describe for the first time a novel bicistronic HC-Ad driving constitutive expression of herpes simplex virus type 1 thymidine kinase (HSV1-TK) and inducible Tet-mediated expression of Flt3L within a single-vector platform. We achieved anti-GBM therapeutic efficacy with no overt toxicities using this bicistronic HC-Ad even in the presence of systemic Ad immunity. The bicistronic HC-Ad-TK/TetOn-Flt3L was delivered into intracranial gliomas in rats. Survival, vector biodistribution, neuropathology, systemic toxicity, and neurobehavioral deficits were assessed for up to 1 year posttreatment. Therapeutic efficacy was also assessed in animals preimmunized against Ads. We demonstrate therapeutic efficacy, with vector genomes being restricted to the brain injection site and an absence of overt toxicities. Importantly, antiadenoviral immunity did not inhibit therapeutic efficacy. These data represent the first report of a bicistronic vector platform driving the expression of two therapeutic transgenes, i.e., constitutive HSV1-TK and inducible Flt3L genes. Further, our data demonstrate no promoter interference and optimum gene delivery and expression from within this single-vector platform. Analysis of the efficacy, safety, and toxicity of this bicistronic HC-Ad vector in an animal model of GBM strongly supports further preclinical testing and downstream process development of HC-Ad-TK/TetOn-Flt3L for a future phase I clinical trial for GBM.
Collapse
|
108
|
Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards CJ, Jankowska B, Uchmanowicz I, Polanski J, Dudek K, Suresh R, Horwood N, Sandoo A, van Zanten JV, Smith JP, Carroll D, Toms TE, Kitas GD, Chitale S, Estrach C, Thompson R, Sathyamurthy S, Goodson N, Toms TE, Panoulas VF, Douglas KM, Kitas GD, Abozaid HS, Fathi NA, Scott DL, Steer S, Galloway J, Dixon W, Mercer L, Watson K, Mark L, Hyrich K, Symmons D, Hirsch G, Klocke R, Toberty E, Coulson E, Saravanan V, Heycock C, Rynne M, Hamilton J, Kelly C, Tsang R, Coulson E, Saravanan V, Heycock C, Hamilton J, Kelly C, El Miedany Y, Palmer D, Collins D, Arnold T, Juarez M, Waller R, Williamson L, Price E, Suppiah R, Doyle A, Rai R, Dalbeth N, Lobo M, Braun J, McQueen F, Cader Z, Filer A, Buckley CD, Raza K, Mirjafari H, Farragher T, Verstappen SM, Bunn D, Charlton-Menys V, Marshall T, Symmons DP, Bruce IN, Steven R, Crilly A, Lockhart JC, Ferrell WR, McInnes IB, Ahmed U, Rabbani N, Filer A, Watts R, Raza K, Thornalley P, Nikiphorou E, Young A, Kiely P, Walsh D, Williams R, Iskandar M, Farragher T, Bunn D, Symmons D, El Miedany Y, El Gaafary M, Palmer D, Filer A, de Pablo P, Allen G, Nightingale P, Jordan A, Jobanputra P, Buckley C, Raza K, Gordon R, Snowden N, Gwynne C, Amos N, Camilleri J, El Miedany Y, El Gaafary M, Youssef S, Palmer D, Silburn S, Pullar T, Vinod K, Fardon T, Scott IC, Kingsley G, Scott DL, Koduri G, Norton S, Young A, Cox N, Prouse P, Dixey J, Williams P, Jones N, Suppiah R, Newton J, Litwic AE, Ledingham JM, Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Koutedakis Y, Kitas GD, Ramachandran Nair J, Mewar D, Long KS, Coulson E, Saravanan V, Heycock C, Hamilton J, Kelly C, El Miedany Y, Youssef S, Palmer D. Rheumatoid Arthritis: Clinical Aspects [322-355]: 322. The Effect of Biologics on Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Systematic Literature Review. Rheumatology (Oxford) 2010. [DOI: 10.1093/rheumatology/keq736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
109
|
Wig S, Bischoff P, Holt M, Collins S, Goodfellow R, Martin J, Rhys-Dillon C, Lyle S, Rowan Phillips J, Mease PJ, Perdok R, Kary S, Kupper H, Humphreys E, Amos N, Nash J, Jones S, McHugh K, Giles J, Kollnberger S, Kuroi K, Maenaka K, Bowness P, El Miedany Y, El Gaafary M, Youssef S, Palmer D, Marshall CL, Harrison PV, Bukhari M, Greenwood MC, Omar F, Hakim AJ, Donnelly SP, Rooney MM, Lanham JG, Tahir H, Mease PJ, Kavanaugh A, Perdok R, Kupper H, Lavie F, Barlow JH, McFarland L, Tindall L, Ravindran J, Perkins P, Ciurtin C, Doufexi D, Bartko J, Roussou E, Phillips JR, Collins S, Lyle S, Goodfellow R, Martin J, Rhys-Dillon C, Thompson B, Rapley T, Broderick W, May C, Kay L, Sandhu J, Packham JC, Healey EL, Jordan K, Garratt AM, Haywood KL, Utriainen L, Cerovic V, McInnes I, Milling S, Ritchlin CT, Mease PJ, Perdok R, Kupper H, Lavie F, Freeston JE, Coates LC, Helliwell PS, Hensor EM, Wakefield RJ, Emery P, Conaghan PG, Skerrett J, van der Weide I, Barlow J, Keat A, van der Heijde D, Braun J, Sieper J, Wishneski C, Vlahos B, Szumski A, Foehl J, Freundlich B, Koenig A, Gatia A, Bartko J, Doufexi D, Roussou E, Kavanaugh A, Gladman D, Chattopadhyay C, Mease P, McInnes IB, Beutler A, Zrubek J, Buchanan J, Parasuraman S, Mack M, Krueger GG, Wazir TU, Cairns AP, Bell A, Giles JL, Shaw J, McHugh K, Ridley A, Bowness P, Kollnberger S, Pritchard GS, Bukhari M, Wilcox L, Freeston JE, Coates LC, Helliwell PS, Hensor EM, Wakefield RJ, Emery P, Conaghan PG, Packham J, Jordan KP, Lebmeier M, Garratt AM, Healey EL, Haywood KL, Ciurtin C, Roussou E, Clarke L, Kay L, Gingold MJ, Bansback N, Guh DP, Cavill C, Porteous R, Kyle SD, Waldron N, Korendowych E, McHugh N, Braun J, van der Heijde AD, Deodhar L, Diekman J, Sieper SI, Kim A, Beutler M, Mack S, Xu J, Zrubek B, Hsu R, Inman O. Spondyloarthropathies (Including Psoriatic Arthritis) [40-69]: 40. Eagle's Syndrome: An Unusual Association with Sero-Negative Arthropathy. Rheumatology (Oxford) 2010. [DOI: 10.1093/rheumatology/keq716] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
110
|
Lloyd M, Makadsi R, Ala A, Connor P, Gwynne C, Rhys Dillon B, Lawson T, Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Muller-Ladner U, Gaylis N, Armstrong GK, Reynard M, Tyrrell H, Joshi N, Loke Y, MacGregor A, Malaiya R, Rachapalli SM, Parton T, King L, Parker G, Nesbitt A, Schiff M, Sheikzadeh A, Formosa D, Domanska B, Morgan D, van Vollenhoven R, Cifaldi M, Roy S, Chen N, Gotlieb L, Malaise M, Langtree M, Lam M, Malipeddi A, Hassan W, El Miedany Y, El Gaafary M, Palmer D, Dutta S, Breslin A, Ahmad Y, Morcos PN, Zhang X, Grange S, Schmitt C, Malipeddi AS, Neame R, Isaacs JD, Olech E, Tak PP, Deodhar A, Keystone E, Emery P, Yocum D, Hessey E, Read S, Blunn KJ, Williams RB, McDowell JA, Rees DH, Young A, Marks JL, Westlake SL, Baird J, Kiely PD, Ostor AJ, Quinn MA, Taylor PC, Edwards CJ, Vagadia V, Bracewell C, McKay N, Collini A, Kidd E, Wright D, Watson K, Williams E, Mossadegh S, Ledingham J, Combe B, Schwartzman S, Massarotti E, Keystone EC, Luijtens K, van der Heijde D, Mariette X, Kivitz A, Isaacs JD, Stohl W, Tak PP, Jones R, Jahreis A, Armstrong G, Shaw T, Westhovens R, Strand V, Keystone EC, Purcaru O, Khanna D, Smolen J, Kavanaugh A, Keystone EC, Fleischmann RM, Emery P, Dougados M, Baldassare AR, Armstrong GK, Linnik M, Reynard M, Tyrrell H, McInnes IB, Combe B, Burmester G, Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Aranda R, Becker JC, Zhao C, Le Bars M, Dougados M, Burmester GR, Kary S, Unnebrink K, Guerette B, Oezer U, Kupper H, Dougados M, Keystone EC, Guerette B, Patra K, Lavie F, Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD, Dubash SR, Linton S, Emery P, Genovese MC, Fleischmann RM, Matteson EL, Hsia EC, Xu S, Doyle MK, Rahman MU, Keystone E, Curtis J, Fleischmann R, Mease P, Khanna D, Smolen J, Coteur G, Combe B, van Vollenhoven R, Smolen J, Schiff M, Fleischmann R, Combe B, Goel N, Desai C, Curtis J, Keystone E, Emery P, Choy E, Van Vollenhoven R, Keystone E, Furie R, Blesch A, Wang CD, Curtis JR, Hughes LD, Young A, Done DJ, Treharne G, van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE, Macey K, Sweetster MT, Lehane PB, Farmer P, Long SG, Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Becker JC, Wu G, Westhovens R, Keystone EC, Kavanaugh A, van der Heijde D, Sinisi S, Guerette B, Keystone EC, Fleischmann R, Smolen J, Strand V, Landewe R, Combe B, Mease P, Ansari Z, Goel N, van der Heijde D, Emery P, Alavi A, Fitzgerald O, Collins ES, Fraser O, Tarelli E, Ng VC, Breshnihan B, Veale DJ, Axford JS, Aletaha D, Alasti F, Smolen JS, Keystone EC, Schiff MH, Rovensky J, Taylor M, John AK, Balbir-Gurman A, Hughes LD, Young A, John Done D, Treharne GJ, Ezard C, Willott R, Butt S, Gadsby K, Deighton C, Tsuru T, Terao K, Suzaki M, Nakashima H, Akiyama A, Nishimoto N, Smolen J, Wordsworth P, Doyle MK, Kay J, Matteson EL, Landewe R, Hsia E, Zhou Y, Rahman MU, Van Vollenhoven R, Siri D, Furie R, Krasnow J, Alecock E, Alten R, Nishimoto N, Kawata Y, Aoki C, Mima T, van Vollenhoven RF, Nishimoto N, Yamanaka H, Woodworth T, Schiff MH, Taylor A, Pope JE, Genovese MC, Rubbert A, Keystone EC, Hsia EC, Buchanan J, Klareskog L, Murphy FT, Wu Z, Parasuraman S, Rahman MU, Kay J, Wordsworth P, Doyle MK, Smolen J, Buchanan J, Matteson EL, Hsia EC, Landewe R, Zhou Y, Shreekant P, Rahman MU, Smolen JS, Gomez-Reino JJ, Davies C, Alecock E, Rubbert-Roth A, Emery P. Rheumatoid Arthritis: Treatment [151-201]: 151. Should we be Looking More Carefully for Methotrexate Induced Liver Disease? Rheumatology (Oxford) 2010. [DOI: 10.1093/rheumatology/keq725] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
111
|
Brunetti-Pierri N, Grove NC, Zuo Y, Edwards R, Palmer D, Cerullo V, Teruya J, Ng P. Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther 2010; 20:479-85. [PMID: 19196177 DOI: 10.1089/hum.2008.084] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Although the desire to develop gene therapy for hemophilia B is high, safety remains a concern. Therefore, improving the therapeutic index of gene therapy vectors is an important goal. Thus, we evaluated the use of three bioengineered factor IX (FIX) variants with improved catalytic activity in the context of the helper-dependent adenoviral vector. The first vector expressed R338A-FIX, an FIX variant with the arginine at position 338 changed to an alanine, which resulted in a 2.9-fold higher specific activity (IU/mg) compared with the wild-type FIX. The second vector expressed FIX(VIIEGF1), a variant with the EGF-1 domain replaced with the EGF-1 domain from FVII, which resulted in a 3.4-fold increase in specific activity. The third expressed R338A + FIX(VIIEGF1), a novel variant containing both aforementioned modifications, which resulted in a 12.6-fold increase in specific activity. High-level, long-term, and stable expression of these three variants was observed in hemophilia B mice with no evidence of increased thrombogenicity compared with wild-type FIX. Thus, these bioengineered FIX variants can increase the therapeutic index of gene therapy vectors by permitting administration of lower doses to achieve the same therapeutic outcome. Furthermore, these variants may also be valuable for recombinant FIX protein replacement therapy.
Collapse
|
112
|
Weaver EA, Nehete PN, Nehete BP, Buchl SJ, Palmer D, Montefiori DC, Ng P, Sastry KJ, Barry MA. Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses 2009; 1:920. [PMID: 20107521 PMCID: PMC2811377 DOI: 10.3390/v1030920] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helper-dependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5-immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.
Collapse
|
113
|
Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G. Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol 2009; 53:305-9. [PMID: 19624298 DOI: 10.1111/j.1754-9485.2009.02074.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The purpose of the present study was to investigate potential prognostic factors in low-grade oligodendrogliomas (LGOs), particularly 1p19q deletion, due to its proven prognostic significance in anaplastic oligodendrogliomas. We carried out a retrospective review of patients with a histological diagnosis of LGO between 1990 and 2000 in Auckland and Wellington, New Zealand. All cases underwent central histopathological review and FISH testing for 1p19q status. Univariate analysis of potential prognostic factors including 1p19q status, age, tumour size, tumour crossing midline, tumour enhancement, extent of surgery and seizures at diagnosis was carried out. Thirty-one patients were eligible and FISH testing was successful in 28 specimens (90%). Twenty-three specimens (82%) had 1p19q deletion; four (14%) had no 1p19q deletion; and one (4%) had 1p deletion alone. At a median follow-up of 87 months (0-147 months), median survival had not been reached and no significant difference in overall survival (OS) based on 1p19q status was detected (1p19q deletion OS 56%; 1p19q intact OS 0%; 1p deletion alone 100% (P = 0.38)). None of the other prognostic factors investigated reached statistical significance. We confirmed the high incidence (82%) of combined 1p19q deletion in LGOs and the feasibility of successful FISH testing in paraffin embedded specimens up to 10-years-old. Analysis of potential prognostic factors was limited by the lack of events during the follow-up period.
Collapse
|
114
|
Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, Fraser IS. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009; 24:1852-61. [PMID: 19369294 DOI: 10.1093/humrep/dep081] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Pilot data have indicated that both doxycycline alone and mifepristone combined with ethinyl estradiol (EE) are effective in stopping episodes of bleeding in Implanon users with troublesome bleeding. We compared four treatments against a placebo in Implanon users and tested whether repeated treatment improved subsequent bleeding patterns. METHOD Implanon users aged 18-45 years were randomized to treatment with (i) mifepristone 25 mg given twice on day 1 followed by 4 days of EE 20 microg; (ii) doxycycline 100 mg twice daily for 5 days; (iii) mifepristone 25 mg given twice on day 1 plus doxycycline 100 mg twice daily for 5 days; (iv) doxycycline 100 mg twice daily with EE 20 microg daily; and (v) placebo twice daily for 5 days. The primary end-point was the number of days of bleeding/spotting immediately following initiation of the first 5-day course of each therapy, compared with placebo. RESULTS There were 204 women assigned to treatment. Mifepristone in combination with either EE or doxycycline was significantly more effective in stopping an episode of bleeding (mean 4.0 days (CI 3.5-4.6) and 4.4 days (CI 3.8-5.2), respectively) than doxycycline alone or in combination with EE, or placebo (6.4 days (CI 4.4-9.2), 6.4 days (CI 4.8-8.6) and 6.4 days (CL 5.1-8.0), respectively). CONCLUSION Mifepristone combined with either EE or doxycycline was significantly more effective than placebo in terminating an episode of bleeding in Implanon users. However there was no improvement in subsequent bleeding patterns. TRIAL REGISTRATION NUMBER ACTR # 012605000206628.
Collapse
|
115
|
Weaver EA, Nehete PN, Buchl SS, Senac JS, Palmer D, Ng P, Sastry KJ, Barry MA. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 2009; 4:e5059. [PMID: 19333387 PMCID: PMC2659436 DOI: 10.1371/journal.pone.0005059] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2008] [Accepted: 02/19/2009] [Indexed: 11/29/2022] Open
Abstract
All studies using human serotype 5 Adenovirus (Ad) vectors must address two major obstacles: safety and the presence of pre-existing neutralizing antibodies. Helper-Dependent (HD) Ads have been proposed as alternative vectors for gene therapy and vaccine development because they have an improved safety profile. To evaluate the potential of HD-Ad vaccines, we compared replication-competent (RC), first-generation (FG) and HD vectors for their ability to induce immune responses in mice. We show that RC-Ad5 and HD-Ad5 vectors generate stronger immune responses than FG-Ad5 vectors. HD-Ad5 vectors gave lower side effects than RC or FG-Ad, producing lower levels of tissue damage and anti-Ad T cell responses. Also, HD vectors have the benefit of being packaged by all subgroup C serotype helper viruses. We found that HD serotypes 1, 2, 5, and 6 induce anti-HIV responses equivalently. By using these HD serotypes in heterologous succession we showed that HD vectors can be used to significantly boost anti-HIV immune responses in mice and in FG-Ad5-immune macaques. Since HD vectors have been show to have an increased safety profile, do not possess any Ad genes, can be packaged by multiple serotype helper viruses, and elicit strong anti-HIV immune responses, they warrant further investigation as alternatives to FG vectors as gene-based vaccines.
Collapse
|
116
|
Abbott B, Abbott R, Adhikari R, Ajith P, Allen B, Allen G, Amin R, Anderson SB, Anderson WG, Arain MA, Araya M, Armandula H, Armor P, Aso Y, Aston S, Aufmuth P, Aulbert C, Babak S, Ballmer S, Bantilan H, Barish BC, Barker C, Barker D, Barr B, Barriga P, Barton MA, Bartos I, Bastarrika M, Bayer K, Betzwieser J, Beyersdorf PT, Bilenko IA, Billingsley G, Biswas R, Black E, Blackburn K, Blackburn L, Blair D, Bland B, Bodiya TP, Bogue L, Bork R, Boschi V, Bose S, Brady PR, Braginsky VB, Brau JE, Brinkmann M, Brooks A, Brown DA, Brunet G, Bullington A, Buonanno A, Burmeister O, Byer RL, Cadonati L, Cagnoli G, Camp JB, Cannizzo J, Cannon K, Cao J, Cardenas L, Casebolt T, Castaldi G, Cepeda C, Chalkley E, Charlton P, Chatterji S, Chelkowski S, Chen Y, Christensen N, Clark D, Clark J, Cokelaer T, Conte R, Cook D, Corbitt T, Coyne D, Creighton JDE, Cumming A, Cunningham L, Cutler RM, Dalrymple J, Danzmann K, Davies G, Debra D, Degallaix J, Degree M, Dergachev V, Desai S, Desalvo R, Dhurandhar S, Díaz M, Dickson J, Dietz A, Donovan F, Dooley KL, Doomes EE, Drever RWP, Duke I, Dumas JC, Dupuis RJ, Dwyer JG, Echols C, Effler A, Ehrens P, Espinoza E, Etzel T, Evans T, Fairhurst S, Fan Y, Fazi D, Fehrmann H, Fejer MM, Finn LS, Flasch K, Fotopoulos N, Freise A, Frey R, Fricke T, Fritschel P, Frolov VV, Fyffe M, Garofoli J, Gholami I, Giaime JA, Giampanis S, Giardina KD, Goda K, Goetz E, Goggin L, González G, Gossler S, Gouaty R, Grant A, Gras S, Gray C, Gray M, Greenhalgh RJS, Gretarsson AM, Grimaldi F, Grosso R, Grote H, Grunewald S, Guenther M, Gustafson EK, Gustafson R, Hage B, Hallam JM, Hammer D, Hanna C, Hanson J, Harms J, Harry G, Harstad E, Hayama K, Hayler T, Heefner J, Heng IS, Hennessy M, Heptonstall A, Hewitson M, Hild S, Hirose E, Hoak D, Hosken D, Hough J, Huttner SH, Ingram D, Ito M, Ivanov A, Johnson B, Johnson WW, Jones DI, Jones G, Jones R, Ju L, Kalmus P, Kalogera V, Kamat S, Kanner J, Kasprzyk D, Katsavounidis E, Kawabe K, Kawamura S, Kawazoe F, Kells W, Keppel DG, Khalili FY, Khan R, Khazanov E, Kim C, King P, Kissel JS, Klimenko S, Kokeyama K, Kondrashov V, Kopparapu RK, Kozak D, Kozhevatov I, Krishnan B, Kwee P, Lam PK, Landry M, Lang MM, Lantz B, Lazzarini A, Lei M, Leindecker N, Leonhardt V, Leonor I, Libbrecht K, Lin H, Lindquist P, Lockerbie NA, Lodhia D, Lormand M, Lu P, Lubinski M, Lucianetti A, Lück H, Machenschalk B, Macinnis M, Mageswaran M, Mailand K, Mandic V, Márka S, Márka Z, Markosyan A, Markowitz J, Maros E, Martin I, Martin RM, Marx JN, Mason K, Matichard F, Matone L, Matzner R, Mavalvala N, McCarthy R, McClelland DE, McGuire SC, McHugh M, McIntyre G, McIvor G, McKechan D, McKenzie K, Meier T, Melissinos A, Mendell G, Mercer RA, Meshkov S, Messenger CJ, Meyers D, Miller J, Minelli J, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Miyakawa O, Moe B, Mohanty S, Moreno G, Mossavi K, Mowlowry C, Mueller G, Mukherjee S, Mukhopadhyay H, Müller-Ebhardt H, Munch J, Murray P, Myers E, Myers J, Nash T, Nelson J, Newton G, Nishizawa A, Numata K, O'Dell J, Ogin G, O'Reilly B, O'Shaughnessy R, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Pan Y, Pankow C, Papa MA, Parameshwaraiah V, Patel P, Pedraza M, Penn S, Perreca A, Petrie T, Pinto IM, Pitkin M, Pletsch HJ, Plissi MV, Postiglione F, Principe M, Prix R, Quetschke V, Raab F, Rabeling DS, Radkins H, Rainer N, Rakhmanov M, Ramsunder M, Rehbein H, Reid S, Reitze DH, Riesen R, Riles K, Rivera B, Robertson NA, Robinson C, Robinson EL, Roddy S, Rodriguez A, Rogan AM, Rollins J, Romano JD, Romie J, Route R, Rowan S, Rüdiger A, Ruet L, Russell P, Ryan K, Sakata S, Samidi M, de la Jordana LS, Sandberg V, Sannibale V, Saraf S, Sarin P, Sathyaprakash BS, Sato S, Saulson PR, Savage R, Savov P, Schediwy SW, Schilling R, Schnabel R, Schofield R, Schutz BF, Schwinberg P, Scott SM, Searle AC, Sears B, Seifert F, Sellers D, Sengupta AS, Shawhan P, Shoemaker DH, Sibley A, Siemens X, Sigg D, Sinha S, Sintes AM, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith ND, Somiya K, Sorazu B, Stein LC, Stochino A, Stone R, Strain KA, Strom DM, Stuver A, Summerscales TZ, Sun KX, Sung M, Sutton PJ, Takahashi H, Tanner DB, Taylor R, Taylor R, Thacker J, Thorne KA, Thorne KS, Thüring A, Tokmakov KV, Torres C, Torrie C, Traylor G, Trias M, Tyler W, Ugolini D, Ulmen J, Urbanek K, Vahlbruch H, Van Den Broeck C, van der Sluys M, Vass S, Vaulin R, Vecchio A, Veitch J, Veitch P, Villar A, Vorvick C, Vyachanin SP, Waldman SJ, Wallace L, Ward H, Ward R, Weinert M, Weinstein A, Weiss R, Wen S, Wette K, Whelan JT, Whitcomb SE, Whiting BF, Wilkinson C, Willems PA, Williams HR, Williams L, Willke B, Wilmut I, Winkler W, Wipf CC, Wiseman AG, Woan G, Wooley R, Worden J, Wu W, Yakushin I, Yamamoto H, Yan Z, Yoshida S, Zanolin M, Zhang J, Zhang L, Zhao C, Zotov N, Zucker M, Zweizig J, Barthelmy S, Gehrels N, Hurley KC, Palmer D. Search for gravitational-wave bursts from soft gamma repeaters. PHYSICAL REVIEW LETTERS 2008; 101:211102. [PMID: 19113401 DOI: 10.1103/physrevlett.101.211102] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2008] [Indexed: 05/11/2023]
Abstract
We present a LIGO search for short-duration gravitational waves (GWs) associated with soft gamma ray repeater (SGR) bursts. This is the first search sensitive to neutron star f modes, usually considered the most efficient GW emitting modes. We find no evidence of GWs associated with any SGR burst in a sample consisting of the 27 Dec. 2004 giant flare from SGR 1806-20 and 190 lesser events from SGR 1806-20 and SGR 1900+14. The unprecedented sensitivity of the detectors allows us to set the most stringent limits on transient GW amplitudes published to date. We find upper limit estimates on the model-dependent isotropic GW emission energies (at a nominal distance of 10 kpc) between 3x10;{45} and 9x10;{52} erg depending on waveform type, detector antenna factors and noise characteristics at the time of the burst. These upper limits are within the theoretically predicted range of some SGR models.
Collapse
|
117
|
Hussain S, Palmer D, Swinson D, Riley P, Wills A, Brown C, Draycott C, El-Modir A, Peake D, Rea D, Chetiyawardana A, Cullen M. A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting. Oncol Rep 2008. [DOI: 10.3892/or.20.1.233] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
118
|
Meyer T, Caplin M, Palmer D, Valle JW, Larvin M, Waters J, Coxon F, Borbath I, Peeters M, Nagano E, Kato H. A phase IB/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4636] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
119
|
Williams LM, Hermens DF, Palmer D, Kohn M, Clarke S, Keage H, Clark CR, Gordon E. Misinterpreting emotional expressions in attention-deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects. Biol Psychiatry 2008; 63:917-26. [PMID: 18272140 DOI: 10.1016/j.biopsych.2007.11.022] [Citation(s) in RCA: 141] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2006] [Revised: 11/17/2007] [Accepted: 11/20/2007] [Indexed: 11/15/2022]
Abstract
BACKGROUND In addition to cognitive impairment, there are disruptions to mood and emotion processing in attention-deficit/hyperactivity disorder (ADHD) but little is known about their neural basis. We examined ADHD disturbances in mood and emotion recognition and underlying neural systems before and after treatment with stimulant medication. METHODS Participants were 51 unmedicated ADHD adolescents and 51 matched healthy control subjects rated for depressed and anxious mood and accuracy for identifying facial expressions of basic emotion. Brain function was recorded using event-related potentials (ERPs) while subjects viewed these expressions. ADHD subjects were retested after 4 weeks, following treatment with methylphenidate (MPH). RESULTS ADHD subjects showed a profile of emotion-related impairment: higher depression and anxiety, deficits in identifying threat-related emotional expressions in particular, and alterations in ERPs. There was a pronounced reduction in occipital activity during the early perceptual analysis of emotional expression (within 120 msec), followed by an exaggeration of activity associated with structural encoding (120-220 msec) and subsequent reduction and slowing of temporal brain activity subserving context processing (300-400 msec). Methylphenidate normalized neural activity and produced some improvement of emotion recognition but had no impact on negative mood. Improvements in neural activity with MPH were consistent predictors of improvement in clinical features of emotional lability and hyperactivity. CONCLUSIONS Objective behavioral and brain function measures of emotion processing may provide a valuable addition to the clinical armamentarium for assessing emotional disturbances in ADHD and the efficacy of stimulants for treating these disturbances.
Collapse
|
120
|
Xiong W, Candolfi M, Kroeger K, Puntel M, Larocque D, Liu C, Palmer D, Ng P, Lowenstein PR, Castro MG. Immune responses to transgenes encoded within gutless adenovirus vectors (HC‐Ads) delivered into the brain. FASEB J 2008. [DOI: 10.1096/fasebj.22.1_supplement.676.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
121
|
Barcia C, Jimenez-Dalmaroni M, Kroeger KM, Puntel M, Rapaport AJ, Larocque D, King GD, Johnson SA, Liu C, Xiong W, Candolfi M, Mondkar S, Ng P, Palmer D, Castro MG, Lowenstein PR. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther 2007; 15:2154-63. [PMID: 17895861 PMCID: PMC2268647 DOI: 10.1038/sj.mt.6300305] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
The main challenge of gene therapy is to provide long-term, efficient transgene expression. Long-term transgene expression from first generation adenoviral vectors (Advs) delivered to the central nervous system (CNS) is elicited in animals not previously exposed to adenovirus (Ad). However, upon systemic immunization against Ad, transgene expression from a first generation Adv is abolished. High-capacity Advs (HC-Advs) provide sustained very long-term transgene expression in the brain, even in animals pre-immunized against Ad. In this study, we tested the hypothesis that a HC-Adv in the brain would allow for long-term transgene expression, for up to 1 year, in the brain of mice immunized against Ad prior to delivery of the vector to the striatum. In naïve animals, the expression of beta-galactosidase from Adv or HC-Adv was sustained for 1 year. In animals immunized prior to vector delivery, expression from a first generation Adv was abolished. These results point to a very long-term HC-Adv-mediated transgene expression in the brain, even in animals that had been immunized systemically against Ad before the delivery of HC-Adv into the brain. This study therefore indicates the utility of HC-Adv as a powerful gene therapy vector for chronic neurological disorders, even in patients who had been pre-exposed to Ad prior to gene therapy.
Collapse
|
122
|
Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AG, Xiong W, Liu C, Mondkar S, Kuoy W, Kang T, McNeil EA, Freese AB, Ohlfest JR, Moore P, Palmer D, Ng P, Young JD, Lowenstein PR, Castro MG. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol 2007; 9:245-58. [PMID: 17522335 PMCID: PMC1907414 DOI: 10.1215/15228517-2007-012] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Expression of the immune-stimulatory molecule Fms-like tyrosine kinase 3 ligand (Flt3L) and the conditional cytotoxic enzyme herpes simplex virus type 1 thymidine kinase (HSV1-TK) provides long-term immune-mediated survival of large glioblastoma multiforme (GBM) models in rodents. A limitation for predictive testing of novel antiglioma therapies has been the lack of a glioma model in a large animal. Dogs bearing spontaneous GBM may constitute an attractive large-animal model for GBM, which so far has remained underappreciated. In preparation for a clinical trial in dogs bearing spontaneous GBMs, we tested and optimized adenovirus-mediated transgene expression with negligible toxicity in the dog brain in vivo and in canine J3T glioma cells. Expression of the marker gene beta-galactosidase (beta-Gal) was higher when driven by the murine (m) than the human (h) cytomegalovirus (CMV) promoter in the dog brain in vivo, without enhanced inflammation. In the canine brain, beta-Gal was expressed mostly in astrocytes. beta-Gal activity in J3T cells was also higher with the mCMV than the hCMV promoter driving tetracycline-dependent (TetON) transgene expression within high-capacity adenovirus vectors (HC-Ads). Dog glioma cells were efficiently transduced by HC-Ads expressing mCMV-driven HSV1-TK, which induced 90% reduction in cell viability in the presence of ganciclovir. J3T cells were also effectively transduced with HC-Ads expressing Flt3L under the control of the regulatable TetON promoter system, and as predicted, Flt3L release was stringently inducer dependent. HC-Ads encoding therapeutic transgenes under the control of regulatory sequences driven by the mCMV promoter are excellent vectors for the treatment of spontaneous GBM in dogs, which constitute an ideal preclinical animal model.
Collapse
|
123
|
Palmer D, Hastings J, Shook R, Conner C, Snell P, Levine BD. Rowing Ergometer Training During Five Weeks of Head Down Tilt Bedrest Preserves Upright Exercise Capacity. Med Sci Sports Exerc 2007. [DOI: 10.1249/01.mss.0000274365.88992.64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
124
|
Xiong W, Goverdhana S, Sciascia SA, Candolfi M, Zirger JM, Barcia C, Curtin JF, King GD, Jaita G, Liu C, Kroeger K, Agadjanian H, Medina-Kauwe L, Palmer D, Ng P, Lowenstein PR, Castro MG. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 2007; 80:27-37. [PMID: 16352528 PMCID: PMC1317549 DOI: 10.1128/jvi.80.1.27-37.2006] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
In view of recent serious adverse events and advances in gene therapy technologies, the use of regulatable expression systems is becoming recognized as indispensable adjuncts to successful clinical gene therapy. In the present work we optimized high-capacity adenoviral (HC-Ad) vectors encoding the novel tetracycline-dependent (TetOn)-regulatory elements for efficient and regulatable gene expression in the rat brain in vivo. We constructed two HC-Ad vectors encoding beta-galactosidase (beta-gal) driven by a TetOn system containing the rtTAS(s)M2 transactivator and the tTS(Kid) repressor under the control of the murine cytomegalovirus (mCMV) (HC-Ad-mTetON-beta-Gal) or the human CMV (hCMV) promoter (HC-Ad-hTetON-beta-Gal). Expression was tightly regulatable by doxycycline (Dox), reaching maximum expression in vivo at 6 days and returning to basal levels at 10 days following the addition or removal of Dox, respectively. Both vectors achieved higher transgene expression levels compared to the expression from vectors encoding the constitutive mCMV or hCMV promoter. HC-Ad-mTetON-beta-Gal yielded the highest transgene expression levels and expressed in both neurons and astrocytes. Antivector immune responses continue to limit the clinical use of vectors. We thus tested the inducibility and longevity of HC-Ad-mediated transgene expression in the brain of rats immunized against adenovirus by prior intradermal injections of RAds. Regulated transgene expression from HC-Ad-mTetON-beta-Gal remained active even in the presence of a significant systemic immune response. Therefore, these vectors display two coveted characteristics of clinically useful vectors, namely their regulation and effectiveness even in the presence of prior immunization against adenovirus.
Collapse
|
125
|
Ung L, Conway EL, Pirotta M, Mast C, Stein AN, Palmer D, Tan J, Fairley CK, Quinn M, Carter R, Garland S. 52. THE AUSTRALIAN WOMEN'S HEALTH SURVEY: ASSESSING THE PSYCHOSOCIAL BURDEN OF HPV RELATED ILLNESS AND PREVENTIVE INTERVENTIONS. Sex Health 2007. [DOI: 10.1071/shv4n4ab52] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
There is increasing recognition of the psychosocial impact of cervical cytology screening programs as well as of the treatment of screening-detected human papillomavirus (HPV) - related disease. The HPV Impact Profile (HIP) includes 29 items with standard response categories representing nine psychosocial impact domains: 'worries and concerns, emotional impact, sexual impact, self image, health perception, cognition, partner and social relations, interaction with doctors and sleep'. Higher scores (0-100) are associated with higher disease burden. The HIP and other generic quality of life instruments such as the Sheehan Disability Scale were administered to women who had experienced and were aware of an HPV related diagnosis in the past 3 months (total n�=�333): 103 women with normal Pap test results (N. Pap), 111 with abnormal Pap tests (58 low grade squamous intraepithelial lesions (LSIL) and 53 high grade SIL (HSIL)), 80 women with biopsy confirmed cervical intraepithelial neoplasia (CIN) (36 CIN1 and 44 CIN 2/3) and 39 women with external genital warts (EGW). In univariate analysis, estimated HIP scores (95% CI) were lower for N.Pap than for all other groups (p�<�0.0001), N. Pap: 25.8 (22.6-29.0); LSIL: 38.8 (34.6-43.1); HSIL: 41.7 (37.2-46.2); CIN1: 41.7 (36.3-47.1); CIN 2/3: 46.6 (41.6-51.5) (p�=�0.013 vs LSIL); EGW: 44.6 (39.4-49.8). The effect was maintained after adjusting for age, race and occupation. On the Sheehan scale, CIN 2/3 and EGW demonstrated increased interference with work and social activities. Results demonstrate: a) HPV infection and disease are associated with significantly increased psychosocial burden, beyond that of the Pap test experience; b) The HIP instrument can adequately distinguish between different HPV conditions; c) Despite their non life threatening nature, the psychosocial impact of genital warts is similar to that of potentially life threatening high grade cervical lesions.
Collapse
|